Cargando…

Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China

BACKGROUND: To compare the survival rates of four timing of treatment initiation for people living with HIV/AIDS provided in China in 2006, 2011, 2015, and 2018, and to investigate the factors impacting survival time. METHODS: A people living with HIV/AIDS retrospective cohort study was in Liuzhou C...

Descripción completa

Detalles Bibliográficos
Autores principales: Ke, Susu, Fang, Quan, Lan, Jianguo, Qiao, Nini, Zhang, Xinhong, Xie, Changping, Fan, Yinguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483872/
https://www.ncbi.nlm.nih.gov/pubmed/37679721
http://dx.doi.org/10.1186/s12889-023-15662-3
_version_ 1785102479409545216
author Ke, Susu
Fang, Quan
Lan, Jianguo
Qiao, Nini
Zhang, Xinhong
Xie, Changping
Fan, Yinguang
author_facet Ke, Susu
Fang, Quan
Lan, Jianguo
Qiao, Nini
Zhang, Xinhong
Xie, Changping
Fan, Yinguang
author_sort Ke, Susu
collection PubMed
description BACKGROUND: To compare the survival rates of four timing of treatment initiation for people living with HIV/AIDS provided in China in 2006, 2011, 2015, and 2018, and to investigate the factors impacting survival time. METHODS: A people living with HIV/AIDS retrospective cohort study was in Liuzhou City from April 2006 to December 2020. The information was obtained from the National Comprehensive AIDS Prevention and Control Information System. Life tables and the Kaplan–Meier method were used to calculate participant survival rates and time. The univariate and multivariate Cox regression models were used to investigate the factors related to survival. RESULTS: 18,543 participants were included in this study. In four periods, the 1-year survival rates were 81%, 87%, 95%, and 95%. The 2-year survival rates were 76%, 85%, 93%, and 94%. The 3-year survival rates were 73%, 84%, 92%, and 94%. Results of multivariate Cox regression showed that sex, age of HIV diagnosis, ethnicity, household registration, occupation, marital status, the timing of treatment, education level, route of HIV transmission, whether receiving antiretroviral therapy (ART), and the count of CD4(+)T cells at baseline (count of CD4(+)T cells at HIV diagnosis) were factors that are significantly correlated with mortality caused by HIV infection. CONCLUSIONS: With the Guidelines updated from 2006 to 2020, the 1-, 2-, and 3-year survival rates of people living with HIV/AIDS in four periods tended to increase. The timing of treatment initiation of the updated edition of the AIDS Diagnostic and Treatment Guidelines (Guidelines) significantly prolonged the survival time of people living with HIV/AIDS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-023-15662-3.
format Online
Article
Text
id pubmed-10483872
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104838722023-09-08 Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China Ke, Susu Fang, Quan Lan, Jianguo Qiao, Nini Zhang, Xinhong Xie, Changping Fan, Yinguang BMC Public Health Research BACKGROUND: To compare the survival rates of four timing of treatment initiation for people living with HIV/AIDS provided in China in 2006, 2011, 2015, and 2018, and to investigate the factors impacting survival time. METHODS: A people living with HIV/AIDS retrospective cohort study was in Liuzhou City from April 2006 to December 2020. The information was obtained from the National Comprehensive AIDS Prevention and Control Information System. Life tables and the Kaplan–Meier method were used to calculate participant survival rates and time. The univariate and multivariate Cox regression models were used to investigate the factors related to survival. RESULTS: 18,543 participants were included in this study. In four periods, the 1-year survival rates were 81%, 87%, 95%, and 95%. The 2-year survival rates were 76%, 85%, 93%, and 94%. The 3-year survival rates were 73%, 84%, 92%, and 94%. Results of multivariate Cox regression showed that sex, age of HIV diagnosis, ethnicity, household registration, occupation, marital status, the timing of treatment, education level, route of HIV transmission, whether receiving antiretroviral therapy (ART), and the count of CD4(+)T cells at baseline (count of CD4(+)T cells at HIV diagnosis) were factors that are significantly correlated with mortality caused by HIV infection. CONCLUSIONS: With the Guidelines updated from 2006 to 2020, the 1-, 2-, and 3-year survival rates of people living with HIV/AIDS in four periods tended to increase. The timing of treatment initiation of the updated edition of the AIDS Diagnostic and Treatment Guidelines (Guidelines) significantly prolonged the survival time of people living with HIV/AIDS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-023-15662-3. BioMed Central 2023-09-07 /pmc/articles/PMC10483872/ /pubmed/37679721 http://dx.doi.org/10.1186/s12889-023-15662-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ke, Susu
Fang, Quan
Lan, Jianguo
Qiao, Nini
Zhang, Xinhong
Xie, Changping
Fan, Yinguang
Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China
title Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China
title_full Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China
title_fullStr Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China
title_full_unstemmed Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China
title_short Survival times of HIV/AIDS in different AIDS Diagnostic and Treatment Guidelines from 2006 to 2020 in Liuzhou, China
title_sort survival times of hiv/aids in different aids diagnostic and treatment guidelines from 2006 to 2020 in liuzhou, china
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483872/
https://www.ncbi.nlm.nih.gov/pubmed/37679721
http://dx.doi.org/10.1186/s12889-023-15662-3
work_keys_str_mv AT kesusu survivaltimesofhivaidsindifferentaidsdiagnosticandtreatmentguidelinesfrom2006to2020inliuzhouchina
AT fangquan survivaltimesofhivaidsindifferentaidsdiagnosticandtreatmentguidelinesfrom2006to2020inliuzhouchina
AT lanjianguo survivaltimesofhivaidsindifferentaidsdiagnosticandtreatmentguidelinesfrom2006to2020inliuzhouchina
AT qiaonini survivaltimesofhivaidsindifferentaidsdiagnosticandtreatmentguidelinesfrom2006to2020inliuzhouchina
AT zhangxinhong survivaltimesofhivaidsindifferentaidsdiagnosticandtreatmentguidelinesfrom2006to2020inliuzhouchina
AT xiechangping survivaltimesofhivaidsindifferentaidsdiagnosticandtreatmentguidelinesfrom2006to2020inliuzhouchina
AT fanyinguang survivaltimesofhivaidsindifferentaidsdiagnosticandtreatmentguidelinesfrom2006to2020inliuzhouchina